Validation of Hemorrhoidal Bleeding Score

Hemorrhoid Bleeding Clinical Trial

Official title:

Validation of Hemorrhoidal Bleeding Score

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03060616
• Other study ID #: SCORE_SG-hémorroide
• Status: Completed
• Start date: September 1, 2016
• Est. completion date: March 15, 2018

Study information

• Verified date: April 2023
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The principal manifestation of hemorrhoidal disease is bleeding; however the severity evaluation is today based on prolapsus (Goligher classification) and bleeding factor is not included. Even if there was some rare score including bleeding in literature , none of them were validated. The aim of the study is first validation of bleeding score .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: March 15, 2018
• Est. primary completion date: March 15, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age>18 years
• consulting for hemorroidal bleeding
• accept to participate

Exclusion Criteria:

• paraplegic or hemiplegic patient
• Misunderstanding of the French language

Related Conditions & MeSH terms

• Hemorrhage
• Hemorrhoid Bleeding
• Hemorrhoids

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	assessment of bleeding score		1 day